Alector Inc (ALEC)

$1.21 +0.07 (6.14%)
Market Cap 124.43M
Revenue (ttm) 100.56M
Net Income (ttm) -119.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -118.39%
Debt to Equity Ratio 0.17
Volume 2,787,800
Avg Vol 2,971,006
Day's Range N/A - N/A
Shares Out 109.15M
Stochastic %K 17%
Beta 0.67
Analysts Hold
Price Target $2.05

Company Profile

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidat...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 231 5660
Address:
131 Oyster Point Boulevard, Suite 600, South San Francisco, United States
Iightning
Iightning Dec. 2 at 2:44 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ALEC **Contract:** Dec 19 $7.5C **Entry:** 0.29 **Exit:** 0.43 **Return:** **+51.28% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Cryptojoe9
Cryptojoe9 Nov. 26 at 10:48 PM
$TMC am guessing this is next $ALEC . Seeing unusual options
1 · Reply
Iightning
Iightning Nov. 26 at 5:42 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.09 Exit: $0.16 | Profit: 83.65% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 3:50 PM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.09 Exit: $0.16 | Profit: 83.65% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:44 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.09 Exit: $0.16 | Profit: 83.65% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 22 at 1:55 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 5:18 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 3:05 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 10:52 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
ZacksResearch
ZacksResearch Nov. 18 at 3:43 PM
$ALEC’s 63% crash in a month — this is the kind of biotech gut-punch that forces a reset. The dementia candidate failed to slow disease progression in a late-stage study, and now the company is rolling out job cuts and shifting its pipeline strategy. Full breakdown on what’s next for ALEC 👉 https://www.zacks.com/stock/news/2792597/alector-stock-plummets-63-in-a-month-heres-what-you-need-to-know?cid=sm-stocktwits-2-2792597-teaser-21387&ADID=SYND_STOCKTWITS_TWEET_2_2792597_TEASER_21387
0 · Reply
Latest News on ALEC
Alector to Participate in the Bank of America CNS Therapeutics Conference

Dec 1, 2025, 4:05 PM EST - 3 days ago

Alector to Participate in the Bank of America CNS Therapeutics Conference

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Nov 26, 2025, 11:00 AM EST - 8 days ago

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 4 weeks ago

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

Oct 22, 2025, 12:07 PM EDT - 6 weeks ago

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic

Oct 21, 2025, 6:45 PM EDT - 6 weeks ago

Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic

Alector shares plunge after dementia drug fails to slow disease progression

Oct 21, 2025, 6:41 PM EDT - 6 weeks ago

Alector shares plunge after dementia drug fails to slow disease progression

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Oct 21, 2025, 4:05 PM EDT - 6 weeks ago

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Oct 10, 2025, 4:32 AM EDT - 7 weeks ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX BDTX CHRS

Alector, Inc. - Special Call

Sep 22, 2025, 9:03 PM EDT - 2 months ago

Alector, Inc. - Special Call

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Sep 16, 2025, 8:00 AM EDT - 2 months ago

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 4:45 PM EDT - 3 months ago

Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alector to Participate in Upcoming Healthcare Conferences

Aug 28, 2025, 8:00 AM EDT - 3 months ago

Alector to Participate in Upcoming Healthcare Conferences

Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:35 AM EDT - 4 months ago

Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript

Alector (ALEC) Q2 Revenue Falls 48%

Aug 7, 2025, 7:52 PM EDT - 4 months ago

Alector (ALEC) Q2 Revenue Falls 48%

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Jul 31, 2025, 4:05 PM EDT - 4 months ago

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Alector Provides Executive Leadership Update

Jun 13, 2025, 4:05 PM EDT - 6 months ago

Alector Provides Executive Leadership Update

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 6 months ago

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 7 months ago

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

Apr 17, 2025, 8:00 AM EDT - 8 months ago

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

GSK

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 1:09 AM EST - 10 months ago

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:05 PM EST - 10 months ago

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Feb 19, 2025, 4:05 PM EST - 10 months ago

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Jan 13, 2025, 8:00 AM EST - 11 months ago

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Dec 4, 2024, 2:20 PM EST - 1 year ago

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Nov 26, 2024, 10:29 AM EST - 1 year ago

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Nov 25, 2024, 4:05 PM EST - 1 year ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Nov 14, 2024, 4:05 PM EST - 1 year ago

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:05 PM EST - 1 year ago

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:53 PM EDT - 1 year ago

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Host Mid-Year Earnings Conference Call

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Alector to Host Mid-Year Earnings Conference Call

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Jul 28, 2024, 8:05 AM EDT - 1 year ago

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 11:23 PM EST - 1 year ago

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 4:05 PM EST - 1 year ago

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Feb 20, 2024, 4:05 PM EST - 1 year ago

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

Feb 8, 2024, 7:00 AM EST - 1 year ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Feb 7, 2024, 7:00 AM EST - 1 year ago

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector Announces Closing of Public Offering

Jan 19, 2024, 9:20 AM EST - 2 years ago

Alector Announces Closing of Public Offering

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Jan 17, 2024, 5:32 PM EST - 2 years ago

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector Announces Pricing of Public Offering of Common Stock

Jan 17, 2024, 8:54 AM EST - 2 years ago

Alector Announces Pricing of Public Offering of Common Stock

Alector Announces Proposed Public Offering of Common Stock

Jan 16, 2024, 4:01 PM EST - 2 years ago

Alector Announces Proposed Public Offering of Common Stock

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16, 2024, 11:12 AM EST - 2 years ago

Alector: Good Data, Huge Cash, No Near Term Catalyst

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Nov 28, 2023, 7:00 AM EST - 2 years ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Alector to Participate in the Stifel Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Alector to Participate in the Stifel Healthcare Conference

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 4:05 PM EST - 2 years ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Oct 27, 2023, 7:00 AM EDT - 2 years ago

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Iightning
Iightning Dec. 2 at 2:44 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ALEC **Contract:** Dec 19 $7.5C **Entry:** 0.29 **Exit:** 0.43 **Return:** **+51.28% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Cryptojoe9
Cryptojoe9 Nov. 26 at 10:48 PM
$TMC am guessing this is next $ALEC . Seeing unusual options
1 · Reply
Iightning
Iightning Nov. 26 at 5:42 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.09 Exit: $0.16 | Profit: 83.65% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 3:50 PM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.09 Exit: $0.16 | Profit: 83.65% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 4:44 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.09 Exit: $0.16 | Profit: 83.65% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 22 at 1:55 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 5:18 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 3:05 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 10:52 AM
1ightning® Options Trade Alert (Actionable) | Buy $ALEC Dec 19 $2 Call | Enter: $0.29 Exit: $0.41 | Profit: 42.38% ROI | https://1ightning.com
0 · Reply
ZacksResearch
ZacksResearch Nov. 18 at 3:43 PM
$ALEC’s 63% crash in a month — this is the kind of biotech gut-punch that forces a reset. The dementia candidate failed to slow disease progression in a late-stage study, and now the company is rolling out job cuts and shifting its pipeline strategy. Full breakdown on what’s next for ALEC 👉 https://www.zacks.com/stock/news/2792597/alector-stock-plummets-63-in-a-month-heres-what-you-need-to-know?cid=sm-stocktwits-2-2792597-teaser-21387&ADID=SYND_STOCKTWITS_TWEET_2_2792597_TEASER_21387
0 · Reply
ZacksResearch
ZacksResearch Nov. 18 at 2:43 PM
$ALEC tumbles 62.5% — what's behind the massive drop? The plunge follows the failure of its late-stage study for latozinemab in FTD-GRN patients, missing key clinical endpoints. Alector is now cutting 49% of its workforce to focus on core programs. Discover the full story and future plans here 👉 https://www.zacks.com/stock/news/2792597/alector-stock-plummets-63-in-a-month-heres-what-you-need-to-know?cid=sm-stocktwits-2-2792597-body-21383&ADID=SYND_STOCKTWITS_TWEET_2_2792597_BODY_21383
0 · Reply
DARKP00L
DARKP00L Nov. 11 at 6:39 PM
$ALEC this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
JasonSmith577
JasonSmith577 Nov. 6 at 4:18 PM
$ALEC holds firm with investor optimism. AITX pushes boundaries with award-winning AI solutions reshaping security and surveillance.
0 · Reply
FeliciaMath
FeliciaMath Nov. 5 at 12:09 AM
not doing well on $ALEC or $PXLW but still holding.
0 · Reply
Pedrogs87
Pedrogs87 Oct. 30 at 3:38 PM
$ALEC https://www.marketbeat.com/instant-alerts/alector-alec-expected-to-announce-quarterly-earnings-on-wednesday-2025-10-29/
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 29 at 5:04 PM
$ALEC dbl hmmm
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Oct. 29 at 3:21 PM
$ALEC Is this still alive? Asking for a friend.
0 · Reply
FeliciaMath
FeliciaMath Oct. 28 at 3:07 PM
$ALEC targeting 2.8-3.3
0 · Reply
FeliciaMath
FeliciaMath Oct. 28 at 2:54 PM
$ALEC bought at 1.53
0 · Reply
Rolo2024
Rolo2024 Oct. 26 at 4:52 PM
$ALEC Target now $2.20 so should see some opportunities!
1 · Reply
estatebuyersmia
estatebuyersmia Oct. 25 at 11:43 AM
$ALEC They have nothing left.... Theyre done...
1 · Reply
bizness1957
bizness1957 Oct. 24 at 4:13 PM
$ALEC red to green with $290 mill in cash plus pipeline
0 · Reply